Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ibrahim Aldoss

Showing results (171-180 of 189) with videos related to

Pageof 19
Sort By:
Blood|February 22, 2022
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemiaShunsuke Kimura, Lindsey Montefiori, Ilaria Iacobucci, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in AdultsKathryn G Roberts, Zhaohui Gu, Debbie Payne-Turner, et al.
Blood Cancer Discovery|December 27, 2023
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal HematopoiesisCaner Saygin, Pu Zhang, Jacob Stauber, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 19

Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
Blood|February 22, 2022
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemiaShunsuke Kimura, Lindsey Montefiori, Ilaria Iacobucci, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in AdultsKathryn G Roberts, Zhaohui Gu, Debbie Payne-Turner, et al.
Blood Cancer Discovery|December 27, 2023
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal HematopoiesisCaner Saygin, Pu Zhang, Jacob Stauber, et al.
Blood|May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi StudyLori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Transplantation and Cellular Therapy|June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances|May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS InvolvementIbrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Blood Advances|October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Pageof 19